But such antibody therapy, known as passive immunization, is also risky.
Gül, N. et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.
Bakema, J. E. & Van Egmond, M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer.
Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Scott, A. M., Wolchok, J. D. & Old, L. J. Antibody therapy of cancer.
Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV.
Rogers, L. M., Veeramani, S. & Weiner, G. J. Complement in monoclonal antibody therapy of cancer.
Edris, B. et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.
Lord, J. D. et al. Refractory colitis following anti-ctla4 antibody therapy: analysis of mucosal FOXP3+ T cells.
Cornell, R. F. et al. Subsequent treatment outcomes of multiple myeloma refractory to CD38-monoclonal antibody therapy.
Elsegeiny, W., Eddens, T., Chen, K. & Kolls, J. K. Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.
